NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for LITFULOâ„¢ (ritlecitinib) to treat adults and adolescents 12 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results